Jubilant Pharmova Past Earnings Performance
Past criteria checks 0/6
Jubilant Pharmova's earnings have been declining at an average annual rate of -35.4%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 9.5% per year. Jubilant Pharmova's return on equity is 0.6%, and it has net margins of 0.6%.
Key information
-35.4%
Earnings growth rate
-35.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -9.5% |
| Return on equity | 0.6% |
| Net Margin | 0.6% |
| Next Earnings Update | 17 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Jubilant Pharmova makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 66,223 | 378 | 22,444 | 0 |
| 30 Sep 23 | 64,977 | -446 | 22,308 | 0 |
| 30 Jun 23 | 64,169 | -1,017 | 21,845 | 0 |
| 31 Mar 23 | 62,817 | -610 | 22,151 | 0 |
| 31 Dec 22 | 61,313 | 964 | 21,726 | 0 |
| 30 Sep 22 | 58,893 | 1,631 | 21,292 | 0 |
| 30 Jun 22 | 59,472 | 3,004 | 20,734 | 0 |
| 31 Mar 22 | 61,302 | 4,139 | 20,739 | 0 |
| 31 Dec 21 | 61,824 | 5,273 | 20,300 | 0 |
| 30 Sep 21 | 66,432 | 6,953 | 19,875 | 0 |
| 30 Jun 21 | 65,771 | 6,993 | 19,448 | 0 |
| 31 Mar 21 | 60,985 | 5,741 | 19,440 | 0 |
| 31 Dec 20 | 92,659 | 8,339 | 22,683 | 0 |
| 30 Sep 20 | 89,744 | 7,759 | 22,527 | 0 |
| 30 Jun 20 | 88,655 | 8,013 | 22,166 | 0 |
| 31 Mar 20 | 59,758 | 6,778 | 18,843 | 0 |
| 31 Dec 19 | 91,486 | 5,385 | 21,451 | 0 |
| 30 Sep 19 | 92,105 | 5,959 | 21,061 | 0 |
| 30 Jun 19 | 92,140 | 5,569 | 19,785 | 0 |
| 31 Mar 19 | 91,108 | 5,745 | 20,093 | 0 |
| 31 Dec 18 | 89,772 | 8,286 | 19,458 | 0 |
| 30 Sep 18 | 86,679 | 7,803 | 18,691 | 0 |
| 30 Jun 18 | 80,402 | 6,982 | 16,971 | 0 |
| 31 Mar 18 | 75,178 | 6,428 | 16,187 | 0 |
| 31 Dec 17 | 68,641 | 6,381 | 14,748 | 0 |
| 30 Sep 17 | 62,545 | 5,449 | 13,610 | 0 |
| 30 Jun 17 | 59,982 | 5,613 | 12,454 | 0 |
| 31 Mar 17 | 58,614 | 5,757 | 12,792 | 0 |
| 31 Dec 16 | 58,013 | 4,763 | 12,382 | 0 |
| 30 Sep 16 | 57,097 | 4,795 | 12,107 | 0 |
| 30 Jun 16 | 57,762 | 4,612 | 11,929 | 0 |
| 31 Mar 16 | 57,491 | 3,918 | 11,674 | 0 |
| 31 Dec 15 | 58,376 | 4,035 | 16,033 | 0 |
| 30 Sep 15 | 59,036 | 2,754 | 15,918 | 0 |
| 30 Jun 15 | 58,117 | 655 | 15,779 | 0 |
| 31 Mar 15 | 58,262 | -578 | 11,284 | 0 |
| 31 Dec 14 | 58,863 | -17 | 14,543 | 0 |
| 30 Sep 14 | 58,837 | 1,529 | 14,636 | 0 |
| 30 Jun 14 | 58,641 | 1,664 | 11,213 | 0 |
| 31 Mar 14 | 58,034 | 1,090 | 14,957 | 0 |
| 31 Dec 13 | 55,983 | -207 | 13,800 | 0 |
| 30 Sep 13 | 54,658 | -1,375 | 13,373 | 0 |
| 30 Jun 13 | 52,497 | 951 | 12,970 | 0 |
Quality Earnings: 530019 has a large one-off loss of ₹1.5B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 530019's current net profit margins (0.6%) are lower than last year (1.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 530019's earnings have declined by 35.4% per year over the past 5 years.
Accelerating Growth: 530019's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 530019 had negative earnings growth (-60.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: 530019's Return on Equity (0.6%) is considered low.